ATRA
ATRA
NASDAQ · Biotechnology

Atara Biotherapeutics Inc

$10.48
+0.67 (+6.83%)
As of May 16, 2:23 AM ET ·
Financial Highlights (FY 2026)
Revenue
76.74M
Net Income
20.77M
Gross Margin
82.4%
Profit Margin
27.1%
Rev Growth
+23.9%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 82.4% 82.4% 58.2% 58.2%
Operating Margin 29.7% 26.7% -3.7% -3.7%
Profit Margin 27.1% 25.7% -2.9% -3.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 76.74M 61.97M 4.60M 4.74M
Gross Profit 63.27M 51.08M 2.67M 2.76M
Operating Income 22.79M 16.56M -170,760 -175,722
Net Income 20.77M 15.09M -132,709 -155,737
Gross Margin 82.4% 82.4% 58.2% 58.2%
Operating Margin 29.7% 26.7% -3.7% -3.7%
Profit Margin 27.1% 25.7% -2.9% -3.3%
Rev Growth +23.9% +23.9% -8.7% +11.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.45M 1.45M 15.40M 16.39M
Total Equity 40.90M 40.90M 18.11M 18.20M
D/E Ratio 0.04 0.04 0.85 0.90
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 24.11M 18.49M -214,542 -195,381
Free Cash Flow -85,981 -141,773